Abivax SA American Depositary Shares

Yahoo Finance • 8 days ago

Is ABIVAX Société Anonyme (ABVX) One of the Hottest Large-Cap Stocks of 2025?

ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the hottest large-cap stocks of 2025. On December 16, Piper Sandler raised the firm’s price target on Abivax to $142 from $112, while maintaining an Overweight rating on the shares. On the sa... Full story

Yahoo Finance • 16 days ago

Here are the most and least likely M&A targets in biotech, according to Truist

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story

Yahoo Finance • 17 days ago

Sector Update: Health Care Stocks Higher Late Afternoon

Health care stocks advanced late Monday afternoon with the NYSE Health Care Index rising 0.6% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 17 days ago

Sector Update: Health Care Stocks Higher in Afternoon Trading

Health care stocks advanced Monday afternoon, with the NYSE Health Care Index up 0.5% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 17 days ago

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of Cormorant’s reportable 13F as... Full story

Yahoo Finance • 18 days ago

Abivax soars on report of Eli Lilly meeting French officials over possible deal

Investing.com -- Abivax shares jumped after fresh media reports revived speculation that U.S. drugmaker Eli Lilly is exploring a takeover of the French biotech company. The stock was up 9% in Paris by 04:21 ET (09:21 GMT) on Monday, while... Full story

Yahoo Finance • 18 days ago

Biggest stock movers Monday: ABVX, RKLB, and more

[Abstract Finance Technology Concept] koto_feja Stock futures edged up Monday morning, signaling a positive open amid year-end rally momentum and holiday-shortened trading. Here are some of Monday's biggest stock movers: BIGGEST STOCK G... Full story

Yahoo Finance • 21 days ago

Abivax to be Added to Nasdaq Biotechnology Index

Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused... Full story

Yahoo Finance • 22 days ago

Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight

The ulcerative colitis market is experiencing steady growth driven by rising disease prevalence and increasing diagnosis rates worldwide. Expanding adoption of advanced biologics, small-molecule therapeutics, and targeted immunomodulators... Full story

Yahoo Finance • 24 days ago

Abivax GAAP EPS of -€2.10

* Abivax press release [https://seekingalpha.com/filing/78948133] (ABVX [https://seekingalpha.com/symbol/ABVX]): Q3 GAAP EPS of -€2.10 * Based on the above, management has concluded that its existing cash and cash equivalents are suffi... Full story

Yahoo Finance • 26 days ago

Earnings week ahead: FDX, NKE, MU, BB, CCL, ACN, and more

[Business.] artisteer/iStock via Getty Images The upcoming week may be a quiet one for earnings reports, but several notable companies are poised to grab investor attention. Tech stalwart BlackBerry (BB [https://seekingalpha.com/symbol/B... Full story

Yahoo Finance • 30 days ago

2 Under-the-Radar Stocks That Have Soared This Year

Key Points TransMedics Group's revolutionary organ care system is driving its strong results. Abivax is a David among Goliaths, and its growth story might just be getting started. 10 stocks we like better than TransMedics Group › Lookin... Full story

Yahoo Finance • last month

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?

Key Points Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. Saturn V now holds 886,332 PHVS shares valued at $22.1 million. PHVS is a new addition, accounting for 4.9% of 13F AUM, which p... Full story

Yahoo Finance • last month

Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow?

Key Points Austin-based Saturn V Capital Management added 1.3 million shares of Amylyx Pharmaceuticals in the third quarter. The overall position increased in value by $41.2 million from quarter to quarter. Saturn V now holds 4.6 million... Full story

Yahoo Finance • last month

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets

Key Points Austin-based Saturn V Capital Management added 1.2 million shares of Dyne Therapeutics during the third quarter. The overall position increased in value by $20 million from quarter to quarter. Saturn V now holds nearly 2.7 mill... Full story

Yahoo Finance • 2 months ago

Which of Goldman's hedge fund favorites is the best buy, as per SA Quant ratings?

[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig Goldman Sachs analysts updated their hedge fund VIP list—the 50 stocks that most frequently appear in the top 10 holdings of fundamental funds—on Thur... Full story

Yahoo Finance • 2 months ago

Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: HSBC upgraded Caterpillar (CAT) to Buy... Full story

Yahoo Finance • 3 months ago

Barclays initiates coverage on U.S. small & mid-cap biotech stocks

Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology I... Full story

Yahoo Finance • 3 months ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8; met primary and a... Full story

Yahoo Finance • 3 months ago

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY AND SAFETY OF OBEFAZI... Full story